Table 4.
Survival during the follow-up period
| First-line cohort (all) | First-line cohort (sorafenib) | Second-line cohort (all) | ||||
|---|---|---|---|---|---|---|
| N = 758 | N = 593 | N = 87 | ||||
| Died (N, %) | 409 | 54.0% | 345 | 58.2% | 46 | 52.9% |
| Survival time, monthsa (mean, SD) | 12.28 | 14.34 | 11.09 | 13.13 | 13.78 | 14.14 |
| Survival time, monthsa (median) | 6.83 | 5.97 | 9.33 | |||
| Patients who survivedb (N, %) | ||||||
| < 1 year | 511 | 67.4% | 424 | 71.5% | 57 | 65.5% |
| ≥ 1 | 247 | 32.6% | 169 | 28.5% | 30 | 34.5% |
| ≥ 2 | 94 | 12.4% | 66 | 11.1% | 14 | 16.1% |
| ≥ 3 | 50 | 6.6% | 32 | 5.4% | 5 | 5.7% |
| ≥ 4 | 30 | 4.0% | 18 | 3.0% | 4 | 4.6% |
SD standard deviation
aTime from cohort index date to death date or censor date (end of MarketScan enrollment or end of study period)
bCounts are not mutually exclusive